EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Value of MRI - T2 Mapping to Differentiate Clinically Significant Prostate Cancer

Andreas Michael Bucher, Jan Egger iD, Julia Dietz, Ralph Strecker, Tom Hilbert, Eric Frodl, Mike Wenzel, Tobias Penzkofer, Bernd Hamm, Felix Kh Chun, Thomas Vogl, Jens Kleesiek und 1 weitere

Journal of Imaging Informatics in Medicine · 26.06.2024 · 37 (6) · 3304-3315

DOI: 10.1007/s10278-024-01150-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Imaging Informatics in Medicine, online erschienen am 26.06.2024. Verfasst von Andreas Michael Bucher und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Diagnostic and Interventional Radiology, Goethe University Frankfurt, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590, Frankf…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Universitätsklinikum Essen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Standardized reporting of multiparametric prostate MRI (mpMRI) is widespread and follows international standards (Pi-RADS). However, quantitative measurements from mpMRI are not widely comparable. Although T2 mapping sequences can provide repeatable quantitative image measurements and extract reliable imaging biomarkers from mpMRI, they are often time-consuming. We therefore investigated the value of quantitative measurements on a highly accelerated T2 mapping sequence, in order to establish a threshold to differentiate benign from malignant lesions. For this purpose, we evaluated a novel, highly accelerated T2 mapping research sequence that enables high-resolution image acquisition with short acquisition times in everyday clinical practice. In this retrospective single-center study, we included 54 patients with clinically indicated MRI of the prostate and biopsy-confirmed carcinoma (n = 37) or exclusion of carcinoma (n = 17). All patients had received a standard of care biopsy of the prostate, results of which were used to confirm or exclude presence of malignant lesions. We used the linear mixed-effects model-fit by REML to determine the difference between mean values of cancerous tissue and healthy tissue. We found good differentiation between malignant lesions and normal appearing tissue in the peripheral zone based on the mean T2 value. Specifically, the mean T2 value for tissue without malignant lesions was (151.7 ms [95% CI: 146.9–156.5 ms] compared to 80.9 ms for malignant lesions [95% CI: 67.9–79.1 ms]; p < 0.001). Based on this assessment, a limit of 109.2 ms is suggested. Aditionally, a significant correlation was observed between T2 values of the peripheral zone and PI-RADS scores (p = 0.0194). However, no correlation was found between the Gleason Score and the T2 relaxation time. Using REML, we found a difference of -82.7 ms in mean values between cancerous tissue and healthy tissue. We established a cut-off-value of 109.2 ms to accurately differentiate between malignant and non-malignant prostate regions. The addition of T2 mapping sequences to routine imaging could benefit automated lesion detection and facilitate contrast-free multiparametric MRI of the prostate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMagnetic Resonance ImagingHumansMaleMiddle AgedRetrospective StudiesAgedProstateDiagnosis, DifferentialImage Interpretation, Computer-AssistedMultiparametric Magnetic Resonance Imaging

Stichwörter der Autor:innen

Multiparametric prostate MRIProstate cancerQuantitative imagingT2 mapping

Autor:innen und Institutionen

  • Institute for Diagnostic and Interventional Radiology, Goethe University Frankfurt, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590, Frankfurt, Germany.
  • Institute for AI in Medicine, University Hospital Essen, Girardetstraße 2, 45131, Essen, Germany. jan.egger@uk-essen.de.
  • Siemens Healthineers AG, (EMEA Scientific Partnerships), Henkestraße 127, 91052, Erlangen, Germany.
  • Advanced Clinical Imaging Technology, Siemens Healthineers International AG, EPFL, QI E, 1015, Lausanne, Lausanne, Switzerland.
  • Department of Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • LTS5, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.

ORCID-Profile: Jan Egger

Förderung

  • Bundesministerium für Bildung und Forschung
  • Universitätsklinikum Essen

Zitieren

APA

Bucher, A. M., Egger, J., Dietz, J., Strecker, R., Hilbert, T., Frodl, E., Wenzel, M., Penzkofer, T., Hamm, B., Chun, F. K., Vogl, T., Kleesiek, J., & Beeres, M. (2024). Value of MRI - T2 Mapping to Differentiate Clinically Significant Prostate Cancer. Journal of Imaging Informatics in Medicine, 37(6), 3304-3315. https://doi.org/10.1007/s10278-024-01150-6

Vancouver

Bucher AM, Egger J, Dietz J, Strecker R, Hilbert T, Frodl E, et al. Value of MRI - T2 Mapping to Differentiate Clinically Significant Prostate Cancer. Journal of Imaging Informatics in Medicine. 2024;37(6):3304-3315. doi:10.1007/s10278-024-01150-6

BibTeX
@article{Bucher2024,
  author = {Bucher, Andreas Michael and Egger, Jan and Dietz, Julia and Strecker, Ralph and Hilbert, Tom and Frodl, Eric and Wenzel, Mike and Penzkofer, Tobias and Hamm, Bernd and Chun, Felix Kh and Vogl, Thomas and Kleesiek, Jens and Beeres, Martin},
  title = {Value of MRI - T2 Mapping to Differentiate Clinically Significant Prostate Cancer},
  journal = {Journal of Imaging Informatics in Medicine},
  year = {2024},
  volume = {37},
  number = {6},
  pages = {3304--3315},
  doi = {10.1007/s10278-024-01150-6}
}
Kostenlos starten →